Emergent Begin Period Cash Flow from 2010 to 2024
| EBS Stock | USD 10.11 0.08 0.80% |
Begin Period Cash Flow | First Reported 2006-12-31 | Previous Quarter 79 M | Current Value 71 M | Quarterly Volatility 141.6 M |
Check Emergent Biosolutions financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Emergent Biosolutions' main balance sheet or income statement drivers, such as Depreciation And Amortization of 135.6 M, Interest Expense of 92.3 M or Total Revenue of 560.8 M, as well as many indicators such as Price To Sales Ratio of 0.11, Dividend Yield of 0.018 or PTB Ratio of 0.18. Emergent financial statements analysis is a perfect complement when working with Emergent Biosolutions Valuation or Volatility modules.
Emergent | Begin Period Cash Flow |
Latest Emergent Biosolutions' Begin Period Cash Flow Growth Pattern
Below is the plot of the Begin Period Cash Flow of Emergent Biosolutions over the last few years. It is the amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities. Emergent Biosolutions' Begin Period Cash Flow historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Emergent Biosolutions' overall financial position and show how it may be relating to other accounts over time.
| Begin Period Cash Flow | 10 Years Trend |
|
Begin Period Cash Flow |
| Timeline |
Emergent Begin Period Cash Flow Regression Statistics
| Arithmetic Mean | 298,712,000 | |
| Geometric Mean | 207,050,823 | |
| Coefficient Of Variation | 73.40 | |
| Mean Deviation | 177,915,333 | |
| Median | 179,338,000 | |
| Standard Deviation | 219,243,720 | |
| Sample Variance | 48067.8T | |
| Range | 667.6M | |
| R-Value | 0.81 | |
| Mean Square Error | 17962.8T | |
| R-Squared | 0.65 | |
| Significance | 0.0003 | |
| Slope | 39,615,668 | |
| Total Sum of Squares | 672949.3T |
Emergent Begin Period Cash Flow History
About Emergent Biosolutions Financial Statements
Emergent Biosolutions shareholders use historical fundamental indicators, such as Begin Period Cash Flow, to determine how well the company is positioned to perform in the future. Although Emergent Biosolutions investors may analyze each financial statement separately, they are all interrelated. The changes in Emergent Biosolutions' assets and liabilities, for example, are also reflected in the revenues and expenses on on Emergent Biosolutions' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Begin Period Cash Flow | 642.6 M | 674.7 M |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Emergent Stock Analysis
When running Emergent Biosolutions' price analysis, check to measure Emergent Biosolutions' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Emergent Biosolutions is operating at the current time. Most of Emergent Biosolutions' value examination focuses on studying past and present price action to predict the probability of Emergent Biosolutions' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Emergent Biosolutions' price. Additionally, you may evaluate how the addition of Emergent Biosolutions to your portfolios can decrease your overall portfolio volatility.